9 recruiting, 8 unknown, 5 completed, 3 active not recruiting. 22 Phase 2, 8 Phase 1, 2 Not applicable, 2 Phase 3.
Follow Irinotecan liposome: new trials by email Literature Review of Irinotecan liposome trials Research Report on Irinotecan liposome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial Biospecimen Collection, Computed Tomography, Fluorouracil - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 20 | 2026-03-02 | 2026-09-21 |
| SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC SCRT, Liposomal Irinotecan, Oxaliplatin - Rectal Cancer, Adenocarcinoma | Not applicable | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 49 | 2025-11-30 | 2026-03-16 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial Ivonescimab, Nimotuzumab, Irinotecan liposome - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 208 | 2025-06-24 | 2025-09-18 |
| Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC Irinotecan Liposome, Capecitabine - Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Sir Run Run Shaw Hospital | 76 | 2024-11-14 | 2024-11-21 |
| Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC Irinotecan liposome, S-1 - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 56 | 2024-11-01 | 2025-01-10 |
| A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC ivonescimab, irinotecan liposome - Small-cell Lung Cancer | Phase 2 | Completed | Zhejiang Cancer Hospital | 60 | 2024-10-16 | 2026-08-27 |
| Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer Irinotecan liposome（40mg/m2）, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Harbin Medical University | 132 | 2024-09-01 | 2024-07-22 |
| Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer Irinotecan Liposome, Bevacizumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2024-08-09 | 2024-08-09 |
| Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety Irinotecan liposome, Adebrelimab, Oxaliplatin - Pancreatic Cancer Metastatic to Liver | Phase 2 | Recruiting | Jiang Long | 40 | 2024-07-16 | 2024-07-31 |
| Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan Irinotecan Liposome - Colorectal Cancer, Solid Tumor | Unknown | Peking University | 933 | 2024-07-15 | 2024-06-05 | |
| Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer Irinotecan Liposome, 5-FU, LV - Metastatic Colorectal Cancer | Phase 2 | Recruiting | West China Hospital | 86 | 2024-06-30 | 2024-08-12 |
| Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer Adebrelimab, Oxaliplatin 100 MG, Irinotecan liposome - Pancreatic Cancer | Phase 2 | Unknown | Fudan University | 87 | 2024-06-05 | 2024-08-09 |
| HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer HR070803, Oxaliplatin, Tegafur - Efficacy and Safety | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 120 | 2024-04-20 | 2024-04-25 |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC Irinotecan Liposome, Anlotinib - Small Cell Lung Cancer Recurrent | Not applicable | Recruiting | Fudan University | 39 | 2024-04-17 | 2025-08-20 |
| A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma simmitinib plus irinotecan liposome, irinotecan liposome, irinotecan - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Shanghai Runshi Pharmaceutical Technology Co., Ltd | 138 | 2024-03-15 | 2024-07-22 |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Irinotecan Liposome, Oxaliplatin, 5-FU - Metastatic Colorectal Cancer | Phase 1 | Unknown | Shanghai Zhongshan Hospital | 78 | 2024-03-11 | 2024-03-19 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors radiotherapy, irinotecan liposome, apatinib - Solid Tumor | Phase 2 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2020-09-01 | 2020-09-30 |
Showing 20 of 30. Sign in to see all of them.
Pancreatic Neoplasms (7) · Colorectal Neoplasms (6) · Nasopharyngeal Carcinoma (2) · Recurrence (2) · Small Cell Lung Carcinoma (2) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Rectal Neoplasms (1) · Somatostatinoma (1) · Stomach Neoplasms (1)
Fudan University (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Roswell Park Cancer Institute (2) · West China Hospital (2) · Academic and Community Cancer Research United (1) · Bristol-Myers Squibb (1) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Harbin Medical University (1) · ImmunityBio, Inc. (1) · Jiang Long (1) · Ming-Yuan Chen (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · Northwestern University (1)
China (15) · United States (12) · Canada (2) · Denmark (1) · Germany (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Afsaneh Barzi, MD (1) · Baorui Baorui Liu, Doctor (1) · Christos Fountzilas (1) · Daniela E Matei, M.D. (1) · Efrat Dotan (1) · Hongli Liu, Professor (1) · Jialei Wang, Doctor (1) · Jing Huang (1) · Mingyu Chen, Ph.D (1) · Nina N Sanford (1) · Olatunji B. Alese, MD (1) · Rachael A Safyan (1) · Renuka Iyer (1) · Susan E Bates (1) · Tanios S Bekaii-Saab (1)
PMID 33835977, PMID 36963200, PMID 37010988, PMID 37056765
P30CA014089 (1), P30CA015083 (1), P30CA060553 (1), U10CA180820 (1), U10CA180868 (1), U10CA180888 (1), ZIABC011078 (1)